The state's bioscience sector got a big boost this week when health information company Sema4 announced plans to move its New York research laboratory and 400 jobs to Connecticut.
Sema4, part of the Mount Sinai Health System, plans to bring the new laboratory and jobs to Stamford, where the company is headquartered.
The company currently has a laboratory in Branford, and the Stamford expansion will bring its total Connecticut workforce to 553.
CBIA's Paul Pescatello, chair of the Connecticut Bioscience Growth Council, called the announcement "great news for Connecticut."
"Sema4 is a breakthrough company, marrying information technology and biotechnology," Pescatello said.
Connecticut offers a very attractive environment to grow along the talent-rich biotech corridor running from New York City to New Haven.
"The company's technology is the scaffold on which the future of the biopharma industry will be built.
"Its research and development are disruptive, changing the way basic and translational medical research is done and, in the process, speeding the delivery of new medicines."
Sema4 offers advanced genome-based diagnostics and builds predictive models of complex disease, enabling doctors and patients to utilize the digital universe of data.
The move was made possible through a $6 million loan from the state Department of Economic and Community Development that allows Sema4 to buy new equipment, upgrade facilities, and create 408 new jobs.
The state will forgive part of the loan if the company meets certain benchmarks.
Governor Dannel Malloy said Sema4 chose Connecticut "thanks to our first-class talent pipeline and exceptional educational institutions."
Company founder Eric Schadt agreed.
"Connecticut offers a very attractive environment for our company to grow along the talent-rich biotech corridor running from New York City to New Haven," he said.
"[There is] a stellar pool of qualified candidates, plus competitively priced commercial real estate and the presence of leading universities and medical centers."